Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Celgene Corporation : to Announce Third Quarter 2017 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CEST

Release date- 03102017 -

SUMMIT, N.J. - Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.

The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Forward Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Contact:

Tel: 908-673-9969

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
06/22CELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
AQ
06/22Celgenes CAR T Cell Therapy Could Be Long-Term Growth Driver
AQ
06/21Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks
AC
06/20ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
AQ
06/19CELGENE CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/19CELGENE CORPORATION : Announces Appointment of Jonathan Biller as Executive Vice..
BU
06/19NASDAQ 100 MOVERS : Jd, regn
AQ
06/19ELOXX PHARMACEUTICALS : Appoints Global Pharmaceutical Leader, Neil Belloff, Exe..
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/15CELGENE : CREATES could face uphill battle in Senate
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Forty Seven Readies $100 Million U.S. IPO 
06/183 THINGS IN BIOTECH, JUNE 17 : Ruxolitinib Climbs Higher 
06/18Tandem Diabetes Care Has Run Up A Lot - Cramer's Lightning Round (6/15/18) 
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
Financials ($)
Sales 2018 14 908 M
EBIT 2018 8 447 M
Net income 2018 4 829 M
Debt 2018 6 033 M
Yield 2018 -
P/E ratio 2018 12,37
P/E ratio 2019 9,75
EV / Sales 2018 4,24x
EV / Sales 2019 3,21x
Capitalization 57 116 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 113 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-24.49%57 116
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373